GIP Receptor Activity May support insulin response and metabolic signaling, particularly when combined with GLP-1 receptor activity
However, glucagon receptor agonism at carefully balanced levels has been proposed based on preclinical and early clinical data to increase energy expenditure, promote fat breakdown (lipolysis), and reduce liver fat content
A study published in The Lancet Diabetes & Endocrinology found that tirzepatide, a first-in-class dual agonist targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, diminishes the risk of major kidney events when compared with dulaglutide, a long-acting GLP-1 receptor agonist, in patients with type 2 diabetes (T2DM)
The FDAs decision was based on data from the FLOW Phase IIIb kidney outcomes trial, which investigated the effects of once-weekly Ozempic 1 mg injections on major kidney and cardiovascular outcomes in adults with type 2 diabetes and CKD
Induction of intestinal Th17 cells by flagellins from segmented filamentous bacteria